8-K 1 e8-k.txt FORM 8-K 1 SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities and Exchange Act of 1934 Date of Report (Date of earliest event reported): July 5, 2000 WATSON PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Nevada 0-20045 95-3872914 (State of jurisdiction) (Commission File No.) (IRS Employer Identification No.)
311 Bonnie Circle Corona, California 92880 (Address of principal executive offices and zip code) Registrant's telephone number, including area code: (909) 270-1400 2 Item 5. Other Events On July 5, 2000, Watson Pharmaceuticals, Inc. (the "Company") announced the expiration of a tender offer to acquire all of the outstanding shares of Schein Pharmaceutical, Inc. ("Schein"). On July 6, 2000, the Company announced that it has accepted, or expects to accept, 26,070,950 shares of common stock of Schein, equaling approximately 77.9% of the total outstanding shares of Schein. The Company announced further that it paid for 24,565,962 shares of Schein common stock and that Notices of Guaranteed Delivery were received for an additional 1,504,988 shares of Schein common stock. The Company expects to pay for such shares after timely receipt of proper documentation. The Company's press releases, dated July 5, 2000, titled "Watson Pharmaceuticals, Inc. Announces Expiration of Its Tender Offer for Schein Pharmaceutical, Inc." and dated July 6, 2000, titled "Watson Pharmaceuticals, Inc. Announces Completion of Tender Offer for Schein Pharmaceutical, Inc." are attached hereto as Exhibits 99.1 and 99.2, respectively. Item 7. Financial Statements, Pro Forma Financial Information and Exhibits (c) Exhibits
Exhibit Number Description ------- ----------- 99.1 Press Release dated July 5, 2000, titled, "Watson Pharmaceuticals, Inc. Announces Expiration of Its Tender Offer for Schein Pharmaceutical, Inc." 99.2 Press Release dated July 6, 2000, titled, "Watson Pharmaceuticals, Inc. Announces Completion of Tender Offer for Schein Pharmaceutical, Inc."
2 3 SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. WATSON PHARMACEUTICALS, INC. Dated: July 7, 2000 /s/ Robert C. Funsten --------------------- Robert C. Funsten Senior Vice President, General Counsel and Secretary 3 4 EXHIBIT INDEX
Exhibit Number Description ------- ----------- 99.1 Press Release dated July 5, 2000, titled, "Watson Pharmaceuticals, Inc. Announces Expiration of Its Tender Offer for Schein Pharmaceutical, Inc." 99.2 Press Release dated July 6, 2000, titled, "Watson Pharmaceuticals, Inc. Announces Completion of Tender Offer for Schein Pharmaceutical, Inc."
4